98 related articles for article (PubMed ID: 3168153)
1. Excretion kinetics of the DNA adducts of cis-diamminedichloroplatinum(II) formed in vitro in rat urine.
Försti A; Takala M; Laatikainen R; Hemminki K
Carcinogenesis; 1988 Oct; 9(10):1745-8. PubMed ID: 3168153
[TBL] [Abstract][Full Text] [Related]
2. The quantitative detection of various Pt-DNA-adducts in Chinese hamster ovary cells treated with cisplatin: application of immunochemical techniques.
Plooy AC; Fichtinger-Schepman AM; Schutte HH; van Dijk M; Lohman PH
Carcinogenesis; 1985 Apr; 6(4):561-6. PubMed ID: 4039227
[TBL] [Abstract][Full Text] [Related]
3. Kinetics of reaction of cis-diamminedichloroplatinum(II) with DNA.
Försti A; Leppälä S; Takala M; Laatikainen R; Hemminki K
Pharmacol Toxicol; 1989 Jan; 64(1):120-5. PubMed ID: 2755902
[TBL] [Abstract][Full Text] [Related]
4. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation.
Fichtinger-Schepman AM; van der Veer JL; den Hartog JH; Lohman PH; Reedijk J
Biochemistry; 1985 Jan; 24(3):707-13. PubMed ID: 4039603
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the DNA damage recognized by an antiserum elicited against cis-diamminedichloroplatinum (II)-modified DNA.
Reed E; Gupta-Burt S; Litterst CL; Poirier MC
Carcinogenesis; 1990 Dec; 11(12):2117-21. PubMed ID: 1979937
[TBL] [Abstract][Full Text] [Related]
6. A simple method for the inactivation of monofunctionally DNA-bound cis-diamminedichloroplatinum (II).
Fichtinger-Schepman AM; vd Veer JL; Lohman PH; Reedijk J
J Inorg Biochem; 1984 Jun; 21(2):103-12. PubMed ID: 6539808
[TBL] [Abstract][Full Text] [Related]
7. Instability of the monofunctional adducts in cis-[Pt(NH3)2(N7-N-methyl-2-diazapyrenium)Cl](2+)-modified DNA: rates of cross-linking reactions in cis-platinum-modified DNA.
Payet D; Gaucheron F; Sip M; Leng M
Nucleic Acids Res; 1993 Dec; 21(25):5846-51. PubMed ID: 8290343
[TBL] [Abstract][Full Text] [Related]
8. Escherichia coli DNA polymerase I: inherent exonuclease activities differentiate between monofunctional and bifunctional adducts of DNA and cis- or trans-diamminedichloroplatinum(II). An exonuclease investigation of the kinetics of the adduct formation.
Bernges F; Dörner G; Holler E
Eur J Biochem; 1990 Aug; 191(3):743-53. PubMed ID: 2167853
[TBL] [Abstract][Full Text] [Related]
9. Bending studies of DNA site-specifically modified by cisplatin, trans-diamminedichloroplatinum(II) and cis-[Pt(NH3)2(N3-cytosine)Cl]+.
Bellon SF; Lippard SJ
Biophys Chem; 1990 Apr; 35(2-3):179-88. PubMed ID: 2397272
[TBL] [Abstract][Full Text] [Related]
10. Antibodies against cisplatin-modified DNA and cisplatin-modified (di)nucleotides.
Terheggen PM; Floot BG; Lempers EL; van Tellingen O; Begg AC; den Engelse L
Cancer Chemother Pharmacol; 1991; 28(3):185-91. PubMed ID: 1855275
[TBL] [Abstract][Full Text] [Related]
11. Immunochemical quantitation of adducts induced in DNA by cis-diamminedichloroplatinum (II) and analysis of adduct-related DNA-unwinding.
Fichtinger-Schepman AM; Baan RA; Luiten-Schuite A; van Dijk M; Lohman PH
Chem Biol Interact; 1985 Nov; 55(3):275-88. PubMed ID: 4075437
[TBL] [Abstract][Full Text] [Related]
12. Mutagenic and genotoxic effects of DNA adducts formed by the anticancer drug cis-diamminedichloroplatinum(II).
Yarema KJ; Lippard SJ; Essigmann JM
Nucleic Acids Res; 1995 Oct; 23(20):4066-72. PubMed ID: 7479066
[TBL] [Abstract][Full Text] [Related]
13. Antibodies elicited against cis-diamminedichloroplatinum(II)-modified DNA are specific for cis-diamminedichloroplatinum(II)-DNA adducts formed in vivo and in vitro.
Poirier MC; Lippard SJ; Zwelling LA; Ushay HM; Kerrigan D; Thill CC; Santella RM; Grunberger D; Yuspa SH
Proc Natl Acad Sci U S A; 1982 Nov; 79(21):6443-7. PubMed ID: 6959129
[TBL] [Abstract][Full Text] [Related]
14. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
15. Iododeoxyuridine chemosensitization of cis-diamminedichloroplatinum(II) in human bladder cancer cells.
Chi KH; Kunugi KA; Kinsella TJ
Cancer Res; 1994 May; 54(10):2701-6. PubMed ID: 8168100
[TBL] [Abstract][Full Text] [Related]
16. X-ray structure of the major adduct of the anticancer drug cisplatin with DNA: cis-[Pt(NH3)2(d(pGpG))].
Sherman SE; Gibson D; Wang AH; Lippard SJ
Science; 1985 Oct; 230(4724):412-7. PubMed ID: 4048939
[TBL] [Abstract][Full Text] [Related]
17. Valuable insight into the anticancer activity of the platinum-histone deacetylase inhibitor conjugate, cis-[Pt(NH3)2malSAHA-2H)].
Brabec V; Griffith DM; Kisova A; Kostrhunova H; Zerzankova L; Marmion CJ; Kasparkova J
Mol Pharm; 2012 Jul; 9(7):1990-9. PubMed ID: 22591133
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation.
Fichtinger-Schepman AM; van der Velde-Visser SD; van Dijk-Knijnenburg HC; van Oosterom AT; Baan RA; Berends F
Cancer Res; 1990 Dec; 50(24):7887-94. PubMed ID: 2253228
[TBL] [Abstract][Full Text] [Related]
19. A novel technique to assay adducts of DNA induced by anticancer agent cis-diamminedichloroplatinum(II).
Sharma M; Jain R; Isac TV
Bioconjug Chem; 1991; 2(6):403-6. PubMed ID: 1805936
[TBL] [Abstract][Full Text] [Related]
20. Ring-substituted diaqua(1,2-diphenylethylenediamine)platinum(II) sulfate reacts with DNA through a dissociable complex.
Bernges F; Holler E
Eur J Biochem; 1992 Sep; 208(3):573-9. PubMed ID: 1396663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
